← Oncology Approval Tracker

FDA DECISION ·

Tevimbra

tislelizumab-jsgr · BeOne Medicines USA

FDA approvalNew dosing regimenGastric and gastroesophageal junction cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adds 400 mg IV every six weeks with platinum and fluoropyrimidine chemotherapy for first-line unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma in adults with tumor PD-L1 expression of at least 1.

LAMPGEN ANALYSIS

Why it matters

The six-week checkpoint schedule is an additional option for this established first-line combination.

What research teams should watch

Reconcile the separate checkpoint and chemotherapy schedules so cycle timing remains clear for patients and pharmacy.

PRIMARY RECORDS

Sources